Cost-utility analysis of venetoclax in combination with obinutuzumab as first-line treatment of chronic lymphocytic leukaemia in Spain Estela Moreno-Martínez; Javier de la Serna-Torraba; Vicente Escudero-Vilaplana; José Ángel Hernández-Rivas; Marina Sánchez-Cuervo; Raquel Sánchez-Hernández;

Assessing the risk of using hazardous drugs in Hospital-at-Home Units: a big data study protocol Mari A. Bernabeu-Martínez; Pedro García-Salom; Amparo Burgos-San José; Luis M. Álvarez-Sabucedo; Carmina Wanden-Berghe; Javier Sanz-Valero;

Classification of antineoplastic drug-induced tissue damage: a Consensus of the Spanish Oncology Pharmacy Group Asunción Albert-Marí; M.a Ángeles Gil-Lemus; David Conde-Estévez; Begoña San José-Ruiz; Inmaculada Jiménez-Pulido; M.a Jesús Esteban-Mensua; Ana Cristina Cercós-Lletí; M.a Sacramento Díaz-Carrasco;